Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia

Nature Clinical Practice Neurology volume 3, pages 250–251 (2007)Cite this article

boxed-textBurn D et al. (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 21: 1899–1907

Cholinesterase inhibitors are a useful first-line treatment in patients with Parkinson's disease who have a combination of cognitive and psychotic behavioral problems

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Aarsland D et al. (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60: 387–392

    Article  Google Scholar 

  2. Fenelon G et al. (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123: 733–745

    Article  Google Scholar 

  3. Williams-Gray CH et al. (2006) Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 20: 477–505

    Article  CAS  Google Scholar 

  4. Emre M et al. (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509–2518

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. CH Williams-Gray is a Patrick Berthoud Clinical Research Fellow based at the Cambridge Centre for Brain Repair and RA Barker is a University of Cambridge Reader in Neurology and Honorary Consultant Neurologist at Addenbrooke's Hospital, both in Cambridge, UK.,

    Caroline H Williams-Gray & Roger A Barker

Authors
  1. Caroline H Williams-Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger A Barker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roger A Barker.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams-Gray, C., Barker, R. Visual hallucinations predict increased benefits from rivastigmine in Parkinson's disease dementia. Nat Rev Neurol 3, 250–251 (2007). https://doi.org/10.1038/ncpneuro0471

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0471

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing